Lyell Immunopharma, Inc.LYELNASDAQ
LOADING
|||
Gross Profit Growth Recovery in Progress
Trending higher, below historical average.
Left:
||||
Year-over-year gross profit growth rate
Latest
87.50%
↓ 30% below average
Average (22q)
124.85%
Historical baseline
Range
High:1150.47%
Low:-192.81%
Volatility
1075.9%
High variability
| Period | Value |
|---|---|
| Q3 2025 | 87.50% |
| Q2 2025 | 14.29% |
| Q1 2025 | -36.36% |
| Q4 2024 | -67.65% |
| Q3 2024 | 161.54% |
| Q2 2024 | 333.33% |
| Q1 2024 | 100.06% |
| Q4 2023 | 0.69% |
| Q3 2023 | -12.57% |
| Q2 2023 | 9.07% |
| Q1 2023 | -111.33% |
| Q4 2022 | 1150.47% |
| Q3 2022 | -113.02% |
| Q2 2022 | 1035.99% |
| Q1 2022 | -192.81% |
| Q4 2021 | -142.40% |
| Q3 2021 | 4.83% |
| Q2 2021 | 575.23% |
| Q1 2021 | -123.92% |
| Q4 2020 | 116.07% |
| Q3 2020 | -65.68% |
| Q2 2020 | 148.25% |
| Q1 2020 | 0.00% |